IH closed enrollment in trial comparing COVID-19 treatment regimens
On Apr. 15, 2021, The National Institute of Allergy and Infectious Diseases (NIAID) announced that the fourth iteration…
Experimental antiviral for COVID-19 was effective in hamster study
On Apr. 15, 2021, the National Institutes of Health announced that the experimental antiviral drug MK-4482 significantly decreased…
INOVIO’s COVID-19 vaccine candidate provided broad cross-reactive immune responses In humans against variants
On Apr. 15, 2021, Inovio Pharmaceuticals announced the results of a study focusing on the human immune responses…
CytoDyn executed agreement with Chiral Pharma to provide up to 200,000 vials of leronlimab to Philippines
On Apr. 15, 2021, CytoDyn announced it had executed an exclusive supply and distribution agreement with Chiral Pharma…
AstraZeneca announced update on the safety of COVID-19 vaccine
On Apr. 14, 2021, following concern raised around thrombotic events, AstraZeneca offered its reassurance on the safety of…
Alternating vaccines trial expanded to include two additional vaccines
On Apr. 14, 2021, researchers running the Com-Cov study, launched in February to investigate alternating doses of the…
Moderna announced clinical progress from mRNA Vaccine
On Apr. 14, 2021, Moderna announced that results from a preclinical study of the Companyï¾’s COVID-19 variant-specific vaccine…
Novavax announced participation in University of Oxford Com-COV2 study comparing mixed COVID-19 vaccine combinations
On Apr. 14, 2021, Novavax announced its participation in an expanded investigator-initiated Phase 2 clinical trial called Comparing…
Mayo Clinic launched new technology platform ventures to revolutionize diagnostic medicine
On Apr. 14, 2021, the Mayo Clinic announced a new technology platform initiative to deliver the next generation…
Most differences in DNA binding compounds found at birth in children conceived by IVF not seen in early childhood
On Apr. 14, 2021, National Institutes of Health researchers reported that a study which compared to newborns conceived…
Allen Discovery Center announced your life history is written in your cells’ mutations
On Apr. 13, 2020, the Allen Discovery Center for Human Brain Evolution announced a study that traced developmental…
NIAID trial of Anti-CD14 antibody to treat COVID-19 respiratory disease began
On Apr. 13, 2021, a clinical trial testing the safety and efficacy of an investigational monoclonal antibody for…
Study linked structural brain changes to behavioral problems in children who snore
On Apr. 13, 2021, a large study of children has uncovered evidence that behavioral problems in children who…
Cardinal Health awarded Strategic National Stockpile contract for PPE storage and distribution
On Apr. 13, 2021, Cardinal Health was awarded a $57.8 million contract, including options that if exercised by…
Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine
As of Apr. 12, 2021, more than 6.8 million doses of the Johnson & Johnson (Janssen) vaccine were…
FDA recommended pause in use of J&J vaccine after adverse events reported
On Apr. 13, 2021, the FDA and CDC announced that they were are reviewing data involving six reported…
Positive topline data showed Fostamatinib met primary endpoint of safety in phase 2 clinical trial in hospitalized COVID-19 patients
On Apr. 13, 2021, Rigel Pharma announced the completion of patient enrollment in a multi-center Phase 2 clinical…
Moderna updated clinical and supply on COVID-19 vaccine program
On Apr. 13, 2021, Moderna announced that new results from a preclinical study of the Companyï¾’s COVID-19 variant-specific…
Health Canada Issued Resverlogix authorization to begin immediate clinical studies of apabetalone for COVID-19
On Apr. 12, 2021, Resverlogix announced that it had successfully received its desired ﾓNo Objection Letterï¾” from Health…
Phase III trial showed subcutaneous administration of investigational antibody cocktail reduced risk of symptomatic COVID-19 infections by 81%
On Apr. 12, 2021, Roche confirmed positive results from the phase III REGN-COV 2069 trial assessing the ability…
Asthma drug budesonide shortened recovery time in non-hospitalised patients with COVID-19
On Apr. 12, 2021, Oxford University reported that early treatment with inhaled budesonide shortened recovery time by a…
FDA authorized new high-throughput, automated system for leading COVID-19 test
On Apr. 12, 2021, Thermo Fisher Scientific announced that the U.S. Food and Drug Administration (FDA) had granted…
Biotechnology | COVID-19 | Life Science News | NIH | Therapeutics | Vaccine
NIH COVID-19 treatment guidelines strongly recommended Use of REGEN-COV in high risk outpatients
On Apr. 9, 2021, Regeneron announced that newly updated National Institutes of Health (NIH) COVID-19 treatment guidelines strongly…
Pfizer and BioNTech requested regulatory agencies expand Emergency Use of COVID-19 vaccine to adolescents
On Apr. 9, 2021, Pfizer announced they had requested amendments to the U.S. Emergency Use Authorization (EUA) of…
Antiviral drug Favipiravir investigated as a possible COVID-19 treatment for at-home recovery in PRINCIPLE trial
On Apr. 8, 2021, Oxford University announced that favipiravir was to be investigated in the UK as part…
ImmunityBio announced single prime hAd5 COVID-19 vaccination induced 10-fold increase in T cell response
On Apr. 8, 2021, ImmunityBio reported initial data indicating that a single subcutaneous injection of the companyï¾’s COVID-19…
Lilly and Incyte phase 3 COV-BARRIER study of baricitinib in COVID-19 patients did not meet endpoint
On Apr. 8, 2021, Eli Lilly and Incyte announced results of COV-BARRIER, a Phase 3 study evaluating baricitinib…
NIH began study of allergic reactions to Moderna, Pfizer-BioNTech COVID-19 vaccines
On Apr. 7, 2021, the NIH announced that a clinical trial was underway to determine whether people who…
WHO Global Advisory Committee on Vaccine Safety reported on AstraZeneca COVID-19 vaccine
On Apr. 7, 2021, the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS) announed…
AIM ImmunoTech announced positive data in phase 1 study Investigating intranasal administration of Ampligen as potential treatment for COVID-19
On Apr. 7, 2021, AIM ImmunoTech announced that it had completed dosing of Cohort 1 in a Phase…